Investing in the Future of Non-Viral
Gene Therapy
With validated human data, a Phase 2b-ready asset, and a scalable platform, Copernicus is advancing a new class of genetic medicines.
Investment Highlights
Clinical Validation
Positive human proof-of-concept in CF
Platform Scalability
Multiple tissues, multiple therapeutic classes
Regulatory Momentum
Two FDA Orphan Drug Designations
Capital Efficiency
Phase 2b fundable with ~$15M
Large Market Opportunity
$11B+ CF market alone
Corporate Deck Download
